- Home
- HDL vs AGIO Comparison
HDL vs AGIO Comparison
Compare HDL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- AGIO
- Stock Information
- Founded
- HDL 2016
- AGIO 2007
- Country
- HDL Singapore
- AGIO United States
- Employees
- HDL N/A
- AGIO N/A
- Industry
- HDL Restaurants
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- AGIO Health Care
- Exchange
- HDL Nasdaq
- AGIO Nasdaq
- Market Cap
- HDL 1.6B
- AGIO 1.4B
- IPO Year
- HDL 2024
- AGIO 2013
- Fundamental
- Price
- HDL $20.44
- AGIO $32.09
- Analyst Decision
- HDL
- AGIO Buy
- Analyst Count
- HDL 0
- AGIO 8
- Target Price
- HDL N/A
- AGIO $56.00
- AVG Volume (30 Days)
- HDL 1.4K
- AGIO 550.4K
- Earning Date
- HDL 05-21-2025
- AGIO 05-01-2025
- Dividend Yield
- HDL N/A
- AGIO N/A
- EPS Growth
- HDL 110.82
- AGIO N/A
- EPS
- HDL 0.06
- AGIO 11.45
- Revenue
- HDL $789,766,000.00
- AGIO $37,035,000.00
- Revenue This Year
- HDL $17.95
- AGIO $27.43
- Revenue Next Year
- HDL $13.32
- AGIO $189.81
- P/E Ratio
- HDL $34.83
- AGIO $2.80
- Revenue Growth
- HDL 10.91
- AGIO 25.96
- 52 Week Low
- HDL $13.94
- AGIO $23.42
- 52 Week High
- HDL $30.00
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- AGIO 65.51
- Support Level
- HDL N/A
- AGIO $29.05
- Resistance Level
- HDL N/A
- AGIO $30.45
- Average True Range (ATR)
- HDL 0.00
- AGIO 1.13
- MACD
- HDL 0.00
- AGIO 0.33
- Stochastic Oscillator
- HDL 0.00
- AGIO 91.98
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.